Eugia Pharma Receives USFDA Approval for Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 µg/50 mL and 400 µg/100 mL Single Dose Flexible Containers (Bags)
Published: December 14, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 µg/50 mL and 400 µg/100 mL Single Dose Flexible Containers (Bags).
Indications for this product include:
- Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting;
- Sedation of non-intubated patients prior to and/or during surgical and other procedures.
Refer to package insert for full prescribing information.